Therapeutic antibodies against osteopontin
US12351625B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 7, 2020 |
| Grant date | Jul 8, 2025 |
| Priority date | — |
| Expiry date | Nov 7, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.